Literature DB >> 8676903

In vitro induction of micronuclei and chromosome aberrations by quinolones: possible mechanisms.

P T Curry1, M L Kropko, J R Garvin, R D Fiedler, J C Theiss.   

Abstract

The bacterial gyrase inhibitors, ciprofloxacin and PD 124816, were tested for clastogenic and aneugenic activity in V79 Chinese hamster lung cells in vitro. Cells were exposed for 3 h, washed free of drug, and subcultured for assessment of various endpoints. For structural chromosomal aberration (SCA) analysis, cells were incubated for 18 h, and treated with Colcemid for 2 h before harvest. For micronucleus (MN) analysis, treated cells were incubated with cytochalasin B (CYB) for 16 h. Aneugenicity was assessed by utilizing antikinetochore antibody to detect kinetochore-containing (K +) MN. Both quinolones induced significant increases in SCAs and MN, indicating clastogenic activity. With both compounds, however, the MN response was apparent at lower doses, and remained much higher throughout the dose range than the SCA response. The induced MN were predominantly K --, indicating that aneugenicity was not playing a major role in their induction. A possible explanation for the chromosome effects is that cross-reactivity of the gyrase inhibitors with mammalian topoisomerase II interferes with the separation of chromatids at anaphase leading to chromosome breaks and MN. Quinolones are known to inhibit resolution of the normally transient topoisomerase II-DNA cleavable complex, which may result in chromosome stickness. Thus, SCAs detected in metaphase cells may be attributed to quinolone-induced inhibition of topoisomerase II prior to mitosis while MN arise in binucleated cells as a result of this effect which interferes with chromatid separation during anaphase.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8676903     DOI: 10.1016/0027-5107(96)00002-4

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  4 in total

1.  Regeneration difficulties in patients with FQAD can limit the use of iPSc-based cell therapy.

Authors:  Dagmara Grot; Katarzyna Wasiak; Jerzy Tyszkowski; Ewelina Stoczynska-Fidelus; Tomasz P Ochedalski; Piotr Rieske
Journal:  Stem Cell Res Ther       Date:  2022-05-21       Impact factor: 8.079

2.  Predictions of genotoxic potential, mode of action, molecular targets, and potency via a tiered multiflow® assay data analysis strategy.

Authors:  Stephen D Dertinger; Andrew R Kraynak; Ryan P Wheeldon; Derek T Bernacki; Steven M Bryce; Nikki Hall; Jeffrey C Bemis; Sheila M Galloway; Patricia A Escobar; George E Johnson
Journal:  Environ Mol Mutagen       Date:  2019-02-27       Impact factor: 3.216

3.  The effect of ciprofloxacin on sperm DNA damage, fertility potential and early embryonic development in NMRI mice.

Authors:  Fatemeh Zobeiri; Rajab-Ali Sadrkhanlou; Siamak Salami; Karim Mardani; Abbas Ahmadi
Journal:  Vet Res Forum       Date:  2012       Impact factor: 1.054

Review 4.  Enrofloxacin-The Ruthless Killer of Eukaryotic Cells or the Last Hope in the Fight against Bacterial Infections?

Authors:  Łukasz Grabowski; Lidia Gaffke; Karolina Pierzynowska; Zuzanna Cyske; Marta Choszcz; Grzegorz Węgrzyn; Alicja Węgrzyn
Journal:  Int J Mol Sci       Date:  2022-03-26       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.